MA55600A - Anticorps anti-ige - Google Patents
Anticorps anti-igeInfo
- Publication number
- MA55600A MA55600A MA055600A MA55600A MA55600A MA 55600 A MA55600 A MA 55600A MA 055600 A MA055600 A MA 055600A MA 55600 A MA55600 A MA 55600A MA 55600 A MA55600 A MA 55600A
- Authority
- MA
- Morocco
- Prior art keywords
- ige antibodies
- ige
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1905150.7A GB2589049C (en) | 2019-04-11 | 2019-04-11 | Anti-IgE antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55600A true MA55600A (fr) | 2022-02-16 |
Family
ID=66809886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055600A MA55600A (fr) | 2019-04-11 | 2020-04-09 | Anticorps anti-ige |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20220177604A1 (fr) |
| EP (1) | EP3953396A1 (fr) |
| JP (1) | JP7586833B2 (fr) |
| KR (1) | KR20210150430A (fr) |
| CN (1) | CN113939540A (fr) |
| AU (1) | AU2020271405A1 (fr) |
| BR (1) | BR112021020329A2 (fr) |
| CA (1) | CA3133941A1 (fr) |
| EA (1) | EA202192785A1 (fr) |
| GB (1) | GB2589049C (fr) |
| IL (1) | IL287035A (fr) |
| MA (1) | MA55600A (fr) |
| MX (1) | MX2021012457A (fr) |
| PH (1) | PH12021552545A1 (fr) |
| SG (1) | SG11202110247XA (fr) |
| WO (1) | WO2020208177A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220148804A (ko) | 2020-01-08 | 2022-11-07 | 아르젠엑스 비브이 | 천포창 장애의 치료 방법 |
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス， インコーポレイテッド | Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート |
| EP4431528A1 (fr) * | 2021-10-29 | 2024-09-18 | Longbio Pharma (Suzhou) Co., Ltd. | Protéine de liaison à un antigène isolée et son utilisation |
| CA3258004A1 (fr) | 2022-06-15 | 2023-12-21 | argenx BV | Molécules de liaison fcrn/hsa et méthodes d'utilisation |
| AU2023298184A1 (en) | 2022-07-01 | 2025-02-13 | Aarhus Universitet | Displacers of ige-fceri |
| CN115724951B (zh) * | 2022-11-15 | 2023-10-03 | 怡道生物科技(苏州)有限公司 | 与11型hpv结合的抗体或其抗原结合片段及其应用 |
| CN120882430A (zh) * | 2023-01-18 | 2025-10-31 | 利西亚治疗公司 | 循环溶酶体靶向抗体缀合物 |
| CN118725128B (zh) * | 2023-03-28 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 抗IgE抗体、检测IgE的试剂和试剂盒 |
| CN119490594B (zh) * | 2023-08-15 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 一种抗免疫球蛋白e的抗体及其应用 |
| EP4530295A3 (fr) * | 2023-09-07 | 2025-05-28 | argenx BV | Antagonistes du fcrn et procédés d'utilisation |
| GB202318512D0 (en) * | 2023-12-04 | 2024-01-17 | argenx BV | Methods of determining potency |
| WO2025229206A1 (fr) * | 2024-05-03 | 2025-11-06 | argenx BV | Molécules de liaison monovalentes anti-iga et procédés d'utilisation |
| WO2025240780A1 (fr) | 2024-05-17 | 2025-11-20 | Excellergy, Inc. | Anticorps et fragments d'anticorps qui se lient à l'ige |
| TW202604967A (zh) * | 2024-06-07 | 2026-02-01 | 美商紐維格醫療公司 | 經修飾之Ｆｃ多肽 |
| WO2026015664A1 (fr) * | 2024-07-10 | 2026-01-15 | Lycia Therapeutics, Inc. | Chimères de ciblage lysosomal de cyclage ciblant l'immunoglobuline e (ige) |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| CA2118508A1 (fr) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2467781C (fr) | 2000-11-20 | 2014-09-23 | Canadian Blood Services | Utilisation d'un anticorps monoclonal dirige contre un globule rouge pour inhiber le systeme reticuloendothelial en vue de traiter la thrombocytopenie |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| WO2004016750A2 (fr) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | Anticorps specifiques du recepteur fc$g(g)riib et procedes d'utilisation de ces anticorps |
| WO2004029207A2 (fr) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Variants fc optimises et methodes destinees a leur generation |
| WO2004035752A2 (fr) | 2002-10-15 | 2004-04-29 | Protein Design Labs, Inc. | Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese |
| EP2368578A1 (fr) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés |
| CA2512974A1 (fr) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | Proteines de fusion fc.gamma.r solubles et leurs procedes d'utilisation |
| EP1592777A4 (fr) | 2003-02-01 | 2008-06-04 | Tanox Inc | Procede destine a produire des anticorps a affinite elevee |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| EP2275443B1 (fr) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Molécule de liaison à l antigène capable de se lier à deux molécules d antigène ou plus de manière répétée |
| GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| CA2934644C (fr) * | 2013-12-24 | 2023-11-21 | Argen-X N.V. | Antagonistes du fcrn et procedes d'utilisation |
| NZ726089A (en) * | 2014-04-30 | 2017-12-22 | Hanall Biopharma Co Ltd | Antibody binding to fcrn for treating autoimmune diseases |
| KR102720769B1 (ko) * | 2015-03-09 | 2024-10-22 | 아르제넥스 비브이 | FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법 |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| GB201707484D0 (en) * | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
-
2019
- 2019-04-11 GB GB1905150.7A patent/GB2589049C/en active Active
-
2020
- 2020-04-09 KR KR1020217034261A patent/KR20210150430A/ko not_active Ceased
- 2020-04-09 US US17/598,033 patent/US20220177604A1/en not_active Abandoned
- 2020-04-09 AU AU2020271405A patent/AU2020271405A1/en active Pending
- 2020-04-09 MX MX2021012457A patent/MX2021012457A/es unknown
- 2020-04-09 CA CA3133941A patent/CA3133941A1/fr active Pending
- 2020-04-09 EP EP20718649.5A patent/EP3953396A1/fr active Pending
- 2020-04-09 CN CN202080038130.8A patent/CN113939540A/zh active Pending
- 2020-04-09 WO PCT/EP2020/060240 patent/WO2020208177A1/fr not_active Ceased
- 2020-04-09 PH PH1/2021/552545A patent/PH12021552545A1/en unknown
- 2020-04-09 BR BR112021020329A patent/BR112021020329A2/pt unknown
- 2020-04-09 EA EA202192785A patent/EA202192785A1/ru unknown
- 2020-04-09 MA MA055600A patent/MA55600A/fr unknown
- 2020-04-09 SG SG11202110247XA patent/SG11202110247XA/en unknown
- 2020-04-09 JP JP2021559827A patent/JP7586833B2/ja active Active
-
2021
- 2021-10-06 IL IL287035A patent/IL287035A/en unknown
-
2025
- 2025-07-02 US US19/257,976 patent/US20250388699A1/en active Pending
- 2025-07-02 US US19/258,059 patent/US20250388700A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250388700A1 (en) | 2025-12-25 |
| CA3133941A1 (fr) | 2020-10-15 |
| GB2589049C (en) | 2024-02-21 |
| GB201905150D0 (en) | 2019-05-29 |
| US20220177604A1 (en) | 2022-06-09 |
| PH12021552545A1 (en) | 2022-07-04 |
| MX2021012457A (es) | 2022-01-04 |
| JP7586833B2 (ja) | 2024-11-19 |
| CN113939540A (zh) | 2022-01-14 |
| EA202192785A1 (ru) | 2022-03-03 |
| BR112021020329A2 (pt) | 2021-12-14 |
| SG11202110247XA (en) | 2021-10-28 |
| GB2589049A (en) | 2021-05-26 |
| WO2020208177A1 (fr) | 2020-10-15 |
| IL287035A (en) | 2021-12-01 |
| JP2022528927A (ja) | 2022-06-16 |
| AU2020271405A1 (en) | 2021-10-14 |
| US20250388699A1 (en) | 2025-12-25 |
| GB2589049B (en) | 2023-12-13 |
| KR20210150430A (ko) | 2021-12-10 |
| EP3953396A1 (fr) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52366A (fr) | Anticorps anti-tl1a optimisés | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| MA53434A (fr) | Anticorps anti-tigit | |
| EP3903817A4 (fr) | Nouvel anticorps anti-ccr8 | |
| EP3883970A4 (fr) | Anticorps anti-b7-h3 | |
| MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
| EP3836960A4 (fr) | Anticorps cd47 thérapeutiques | |
| EP3762030A4 (fr) | Anticorps anti-cd73 et utilisations associées | |
| MA52212A (fr) | Anticorps multivalent | |
| EP4377360A4 (fr) | Anticorps anti-cd3 | |
| IL287035A (en) | Anti-ige antibodies | |
| EP3735427A4 (fr) | Anticorps anti-mct1 et utilisations associées | |
| EP3752536A4 (fr) | Anticorps anti-her2 | |
| MA52152A (fr) | Anticorps | |
| MA56466A (fr) | Anticorps anti-epha4 | |
| EP4271712A4 (fr) | Anticorps anti-hvem | |
| EP4081547A4 (fr) | Nouveaux anticorps anti-fgfr2b | |
| EP3831851A4 (fr) | Anticorps anti-btla | |
| MA55705A (fr) | Anticorps bispécifiques | |
| MA52190A (fr) | Anticorps anti-trem-1 et utilisations associées | |
| EP3746120A4 (fr) | Anticorps anti-pd-1 | |
| EP3998286A4 (fr) | Anticorps bispécifique symétrique tétravalent | |
| EP4169952A4 (fr) | Anticorps anti-trop2 | |
| EP3852779A4 (fr) | Anticorps anti-klrg1 | |
| EP4081539A4 (fr) | Nouveaux anticorps anti-fgfr2b |